Advisors to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer’s drug donanemab.
(Image credit: Andrew Harnik)
FDA advisors strongly back new Alzheimer’s drug, despite risks and limitations from NPR Jon Hamilton
